We used 5 published preclinical datasets that contained 3 studies reported as αPD-L1 treatment-sensitive (Lan et al, 2018; Sceneay et al, 2019; Efremova et al, 2018) (Data ref: Lan et al, 2018; Data ref: Sceneay et al, 2019; Data ref: Efremova et al, 2018) and 2 studies reported as αPD-L1 treatment-insensitive (Sceneay et al, 2019) (Data ref: Sceneay et al, 2019) and RENCA-PDL1 tumor cells from this study) (see Methods). The gene discussed is CD274; the disease is neoplasm.